Screener
Jade Biosciences JBIO JADE201 — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| JADE101 external research and development costs | $15,423 | $9,767 |
| JADE201 external research and development costs | 2,877 | 5,154 |
| JADE301 external research and development costs | 5,922 | 733 |
| Research and development personnel-related costs (including stock-based compensation) | 10,648 | 3,952 |
| Other research and development costs | 1,183 | 417 |
| General and administrative personnel-related costs (including stock-based compensation) | 5,298 | 1,713 |
| General and administrative professional, consulting, and other fees | 2,094 | 1,648 |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's JADE201 — research and development expense?
- Jade Biosciences (JBIO) reported JADE201 — research and development expense of $2.88M in Q1 2026.
- How has Jade Biosciences's JADE201 — research and development expense changed year-over-year?
- Jade Biosciences's JADE201 — research and development expense decreased by 44.2% year-over-year, from $5.15M to $2.88M.
- What does JADE201 — research and development expense mean?
- This metric represents the total costs incurred by the JADE201 business segment for research and development activities, including preclinical studies, drug discovery, and clinical trial preparation. It reflects the company's investment in advancing its specific therapeutic pipeline and pipeline-enabling technologies. Monitoring this expenditure helps investors assess the pace of innovation and the capital intensity required to bring the segment's drug candidates toward regulatory approval.
Ask your AI about Jade Biosciences's jade201 — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude